Rafa Laboratories

Company

Rafa Laboratories develops one asset, approved (nogapendekin alfa inbakicept-pmln in bcg-unresponsive non-muscle invasive bladder cancer). Mostly protein or enzyme acting on IL2RB, IL2RG and IL15RA.

1
Asset
Furthest stage
Approved
3
Trials
3
Signals

Pipeline

1
  • nogapendekin alfa inbakicept-pmln

    IL-15 superagonist enhances natural killer and T-cell responses to support vaccine-mediated cancer prevention.

    Approved, Protein or enzyme, IL2RB, IL2RG, bcg-unresponsive non-muscle invasive bladder cancer, bladder cancer, Partner

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Trials3
  • Signals11
  • Similar companies6

Intelligence